Accueil / Tag Archives: Product/Service

Tag Archives: Product/Service

GlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia

Thursday, May 25th 2017 at 1:25pm UTC ROCKVILLE, Md.–(BUSINESS WIRE)– GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the European Commission, based on a favorable recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products, has granted orphan designation for the company’s drug candidate GMI-1271 for the treatment of …

Plus »

Neural Analytics Announces Data that Demonstrates its Portable Transcranial Doppler Technology Can Assess Early Strokes With More than 95 Percent Accuracy

Wednesday, May 24th 2017 at 3:30pm UTC Data Presented at 26th European Stroke Conference LOS ANGELES–(BUSINESS WIRE)– Neural Analytics Inc., a medical device company developing and commercializing technology to measure, diagnose and track brain health, today announced initial results of the EXPEDITE clinical study showing its Transcranial Doppler Technology Platform …

Plus »

Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases

Tuesday, May 23rd 2017 at 12:30pm UTC Strengthens IP position in the US, complements grants in other key markets and protects further development of small molecule drugs capable of penetrating the blood-brain barrier MARTINSRIED, Germany–(BUSINESS WIRE)– Origenis GmbH, a privately held biopharmaceutical company developing novel therapeutics to fight neurodegenerative and …

Plus »

Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen

Tuesday, May 23rd 2017 at 8:01pm UTC Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen’s focus on strategic growth initiatives and generates near-term value LAUSANNE, Switzerland & WALTHAM, Mass.–(BUSINESS WIRE)– Debiopharm International SA (Debiopharm –, part of Debiopharm Group™, a Switzerland-based …

Plus »

Clovis Oncology Announces Presentations at 2017 ASCO Annual Meeting

Tuesday, May 23rd 2017 at 12:00pm UTC Updates on rucaparib clinical trials in multiple solid tumors and therapy settings at ASCO Annual Meeting; top-line data from ARIEL3 pivotal study anticipated by end of June BOULDER, Colo.–(BUSINESS WIRE)– Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that abstracts highlighting progress in the …

Plus »

Octapharma réaffirme son engagement fort envers les patients atteints d’hémophile A avec la publication de nouvelles données cliniques sur la prophylaxie personnalisée avec nuwiq® basée sur l’analyse PK, suivant l’approche NuPreviq

Wednesday, May 24th 2017 at 1:30pm UTC LACHEN, Suisse–(BUSINESS WIRE)– Octapharma annonce de nouvelles données cliniques positives chez 66 patients préalablement traités (PPT) pour hémophilie A sévère (HA) ayant bénéficié d’une prophylaxie personnalisée basée sur une analyse pharmacinetique (PK) avec Nuwiq®, suivant l’approche NuPreviq. Les données de l’étude NuPreviq (GENA-21, …

Plus »

Clinical Ink and endpoint Announce Industry-First Alliance

Tuesday, May 23rd 2017 at 12:00pm UTC eSource and IRT Integration Simplifies the Site Experience SAN FRANCISCO & PHILADELPHIA–(BUSINESS WIRE)– endpoint Clinical, the leading global interactive response technology (IRT®) company, and Clinical Ink, the pioneering provider of eSource and patient engagement technologies, have teamed up to integrate IRT and eSource …

Plus »

Sunovion Announces Utibron™ Neohaler® (indacaterol/glycopyrrolate) Inhalation Powder Data Showing Lung Function and Health-Related Quality of Life Improvement in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Tuesday, May 23rd 2017 at 1:18pm UTC – Presentations at the American Thoracic Society 2017 International Conference (ATS 2017) also included long-term safety data and pooled analyses of pivotal studies – MARLBOROUGH, Mass.–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced that multiple data analyses from two Phase 3 studies demonstrating that …

Plus »

BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)

Tuesday, May 23rd 2017 at 11:00am UTC ALAMEDA, Calif.–(BUSINESS WIRE)– BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that BioTime, and its subsidiary Cell Cure Neurosciences Ltd., will be featured in two presentations at the 16th National Life …

Plus »

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer

Tuesday, May 23rd 2017 at 8:34pm UTC KEYTRUDA Now Approved for Patients with MSI-H or Mismatch Repair Deficient Solid Tumors That Have Progressed Following Prior Treatment and Who Have No Satisfactory Alternative Treatment Options, Which Includes MSI-H or Mismatch Repair Deficient Colorectal Cancer That Has Progressed Following Treatment with a …

Plus »
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
Vous appréciez cet article ? Faites-nous part de vos commentaires.
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
Retrouvez nous sur
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...